Pharmacogenetics of Response to GLP1R Agonists

Pharmacogenetics of Response to GLP1R Agonists
Conditions:   Obesity;   Diabetes Type 2
Intervention:   Drug: Semaglutide Pen Injector [Ozempic]
Sponsor:   University of Maryland, Baltimore

Source: View full study details on

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 3, 2022Comments | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine